Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Iptacopan · Fabhalta, LNP-023

Small molecule · Inhibitor of complement factor B (CFB) · developed by Novartis

Approved FDA, Dec 2023
NVS Developer
2 Registered trials

What is Iptacopan?

Iptacopan is an orally available small-molecule inhibitor of complement factor B. It binds factor B and prevents formation of the alternative pathway C3 convertase, limiting C3 cleavage and downstream complement activation. It is studied in atypical hemolytic uremic syndrome and lupus nephritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Fabhalta, LNP-023
Drug type
Small molecule
Targets
complement factor B (CFB)
Mechanism
Inhibitor of complement factor B (CFB)
Pathways
alternative complement pathway, C3 convertase (C3bBb) formation, terminal complement (membrane attack complex)
Therapy area
Hematology, Renal & urology
Developer
Novartis (NVS)
FDA status
Approved as Fabhalta (December 5, 2023), NDA218276 · FDA label
UNII
8E05T07Z6W

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05795140 Phase 3 Atypical Hemolytic Uremic Syndrome Recruiting NVS
NCT05268289 Phase 2 Lupus Nephritis Terminated NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atypical Hemolytic Uremic SyndromeLupus Nephritis

More from Novartis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Iptacopan

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.